Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.

Frontiers in bioscience (Elite edition) - 1 Jun 2011

Wagh Vilas, Chile Shailaja, Monahar Sonal, Pal Bikas Chandra, Bandyopadhyay Santu, Sharma Somesh, Joshi Kalpana

Abstract excerpt

The deregulated activity of the Bcr-Abl tyrosine kinase provides a rational basis for the development therapeutics in all phases of Chronic Myelogenous Leukemia (CML). Although a well studied imatinib therapy has clinical success against CML, resistance to imatinib due to mutations in the kinase domain, especially T315I poses a major problem for the ultimate success of CML therapy by this agent. Herein we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Piperazines

Share to Plant Extracts

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 21622134
DOI: 10.2741/e331

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.PMID 21622134Read ↗

MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.Semantic proximity Read ↗

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.Semantic proximity Read ↗

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacySemantic proximity Read ↗

Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.Semantic proximity Read ↗

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.Semantic proximity Read ↗

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid LeukemiaSemantic proximity Read ↗

Targeting BCR-ABL1-positive leukaemias: a review articleSemantic proximity Read ↗

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.Semantic proximity Read ↗

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.Semantic proximity Read ↗

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-AblSemantic proximity Read ↗

The second generation of BCR-ABL tyrosine kinase inhibitors.Semantic proximity Read ↗

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.